Gossamer pauses enrollment of lymphoma med, citing risk-benefit profile

Gossamer bio took a few steps forward in December when a high blood pressure med passed a phase 2 trial. But now, the biotech is taking a couple steps back with news that enrollment is being paused for its second clinical-stage asset due in part to the med’s risk-benefit profile.